Background: As a risk-factor population for HIV infection, unsettled populations, in particular, refugees and migrants are understudied.
Background: NRTI class of drugs though they cause mitochondrial toxicity, owing to their cost is the preferred class of drugs in resource-limited settings like India, hence there is a greater need to identify a novel biomarker of mitochondrial toxicity. In this study mitochondrial dysfunction was estimated from peripheral blood mononuclear cells (PBMCs) and the utility of mitochondrial DNA (mtDNA) as a marker of mitochondrial toxicity was evaluated.
Methods & Materials: In this longitudinal observational study, 40 HIV -1 infected patients treated with NRTI based regimen and 57 HIV-1 infected ART untreated patients were followed for 18 months at an interval of 6 months and data were compared with 24 HIV uninfected controls. Mitochondrial dysfunction was determined from mtDNA content by real time PCR, mitochondrial membrane potential damage (total lymphocyte m low ) by flow cytometry and ND1gene of mtDNA was sequenced.
Results: Among the HIV infected, mitochondrial dysfunction was more pronounced in the ART untreated than the treated. mtDNA content and total lymphocyte m low (p=<0.0001) were significantly different among the HIV infected than the controls. Out of the 22 mtDNA variants observed in HIV infected individuals, 27% were found to be associated with mitochondrial mediated pathogenic conditions, distibuted in 10% of on ART and in 8% of ART untreated . mtDNA content was significantly(p<0.0001) reduced in both the HIV infected groups, ART untreated had 83.3(65.56-113) and treated had 92.53(68.64-126.7), than the controls(127.5(110.6-167.7)) throughout the follow up, however it did not differ significantly among the HIV infected. Analysis of mtDNA content in relation to the adverse events, though differed significantly at the first (p= 0.014) and second visit (p= 0.029) was increased in the subsequent visits among the patients symptomatic for toxicity.
Conclusion: Mitochondrial dysfunction is evident among both the treated and untreated HIV-1 infected patients of South India. As mtDNA depletion failed to relate consistently with laboratory adverse events during the complete follow up, measuring mtDNA content in PBMC alone may not be sufficient enough to predict or monitor changes in NRTI associated mitochondrial toxicity. 
Background:
The HIV epidemic in India is concentrated among High Risk Groups and continues to be high among MSM population. Pre-exposure prophylaxis(PrEP) has shown promising results in recent trials. The potential of PrEP as an effective HIV preventive strategy among MSM remains to be studied in India.
Methods & Materials: A structured questionnaire was administered to MSM selected by snowball sampling technique. Individual risk behaviours and demographics were categorised as high, moderate and low risk for HIV and a composite risk score was calculated. To assess the agreement between calculated and self-perceived risk, kappa statistic was used. Bivariate logistic regression was used to ascertain determinants of willingness to use PrEP and to study the anticipated drift in risk compensation behavior with PrEP use.
Results: Data from the initial 55 respondents of this multi-city study are analyzed. The average respondents were predominantly Kothi (31%), found their partners online (83%), had three or more sexual partners in the previous three months (44%), had anal sex less than once a month (45%), used condoms all the time while having anal sex (55%), and considered HIV a risk for them (67%). There was no agreement between self-perceived risk for HIV and calculated composite risk (Kappa= -0.2182, p-value>0.05). Majority (87%) reported willingness to use PrEP which was strongly associated with self-perceived risk of HIV (OR=5.70, p = 0.009). Willingness to use PrEP remained high even after learning about the need for concurrent condom use (OR= 10.83, p = 0.009), regular HIV tests (OR= 30, p = 0.003) and a daily dosing schedule (OR = 12.19, p =0.007 Background: The advent of Highly Active Antiretroviral Therapy (HAART) has reduced HIV/AIDS related morbidity and mortality, so more people with HIV/AIDS live longer. This study aims to determine the health related quality of life of HIV/AIDS patients on HAART at Ahmadu Bello University Teaching Hospital (ABUTH) Zaria.
Methods & Materials:
A cross-sectional descriptive study among 384 HIV patients on HAART at ABUTH was conducted in April 2015 with the sample obtained by a systematic sampling process. A structured, interviewer administered questionnaire was used to assess the health-related quality of life of the respondents and the data was analyzed using SPSS Version 21. Ethical approval was obtained from the Ethical review committee while written informed consent was obtained from all respondents.
Results: Majority of the respondents were females (64.3%), with about 50% in stage 1 of the disease, 40% in stage 2 and the remainder in stage 3. About 55% had CD4 count of 200-500cell/mm 3 , 34% had greater than 500cells/mm3 and 11% had less than 200 cells/mm3. Only 7.8% of respondents were dependent on Alcohol and smoking while 79.6%were still engaged in paid work.A total of 22.9% of respondents had lack of energy while 17.2% experienced pain and 15.6% had drug allergy.
The domain with the lowest score was the psychological domain (5.99),followed by social domain (6.27), physical domain(7.89) and the socio-demographic domain (38.46) which the domain with the highest score. There was statistically significant relationship between CD4 count of respondents and their clinical stage (P <0.0001), but no statistically significant relationship between age and suicidal thoughts, age and suicidal attempt, sex and suicidal thoughts and between sex and suicidal attempt (p= 0.05) Conclusion: Majority of respondents had low quality of life in the psychological, physical and social domains and high quality of life in the socio-demographic domain of the health related quality of life (HRQOL). These findings highlight the need for enhanced psycho-social support, effective management of symptoms and a better environment for improving health related quality of life among people living with HIV/AIDS. http://dx.doi.org/10. 1016/j.ijid.2016.02.603 
